Yee, Karen S.
Alexanderian, David
Martin, Susan
Olayinka-Amao, Bimpe
Whiteman, David A. H. http://orcid.org/0000-0001-6383-9338
Funding for this research was provided by:
Shire, a Takeda company
Takeda Pharmaceutical Company
Takeda Development Center Americas, Inc
Article History
Received: 18 July 2023
Accepted: 24 March 2024
First Online: 12 April 2024
Declarations
:
: These studies were approved by the relevant institutional review boards/institutional ethics committees and were conducted in compliance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. For all patients, written informed consent was obtained from the parent(s) or legally authorized guardian(s); assent from the patient was also acquired, if applicable.
: Not applicable.
: KSY was an employee of Takeda Development Center Americas, Inc. and stockholder of Takeda Pharmaceuticals Company Limited at the time of the analysis (current affiliation is Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease, Boston, MA, USA). DA was an employee of Takeda Development Center Americas, Inc. and stockholder of Takeda Pharmaceuticals Company Limited at the time of this study and of the writing of the manuscript (current affiliation is Merck). SM and BO-A are employees of RTI Health Solutions, and were contracted by Takeda to perform this analysis. DAHW is an employee of Takeda Development Center Americas, Inc. and stockholders of Takeda Pharmaceuticals Company Limited.